Find out more at www.calprotectin.co.uk 11 Faecal Calprotectin POC Faecal calprotectin concentrations are widely acknowledged to correlate to the degree of mucosal inflammation in the gut. However, results are often not available at the point of decision making. A recent study by Derwa et al.4 regarding the factors effecting clinical decision making in IBD found that: ‘almost 60% of patients that were referred for investigation had no evidence of mucosal inflammation’ The study went on to conclude that: Rapid The BÜHLMANN Quantum Blue is a compact device that can be used in clinics or laboratories to give rapid quantitative results in just 15 minutes making results available to support the clinical decision making process. Accurate Numerous publications over the years have demonstrated the correlation of the result from the Quantum Blue assays to the health of the gut and the clinical outcome [Figure2]6. Standardised For over 10 years BÜHLMANN has specialised in calprotectin testing . It has the broadest range of faecal calprotectin assays available, providing assays for large central laboratories, smaller spoke laboratories, IBD clinics and for patient self-testing at home. Because the assays are all manufactured together they are all standardised, giving consistent results and cut-off values in the various locations [Figure 3]8. By working alongside traditional laboratory methods, POC testing can enhance the service that is provided by developing new pathways of care, supporting timely diagnosis, monitoring and treatment of patients. Flexible: All the Quantum Blue assays offer: ■ Single use tests: □ No need to batch samples □ Individually packaged test to maintain quality until use ■ Simple bench top reader (the size of a desk top telephone) □ Used as a stand-alone device or connected to a PC ■ Controls included within each kit ■ High correlation to traditional ELISA methods References: 1. C. Rentsch et al. Pharmacist-led proactive therapeutic drug monitoring with infliximab: utility of and cost-saving with the use of a rapid assay for assessing drug level. ECCO 2018. 2. A. Strik et al. Validation of the Quantum Blue Infliximab level rapid test in clinical practice of patients with inflammatory bowel disease. ECCO 2018. 3. I. Lindsjo et al. Patient-near infliximab trough- level testing by a novel quantitative rapid test: The Quantum Blue Infliximab test. UEGW 2016. 4. Y. Derwa et al. Factors affecting clinical decision- making in inflammatory bowel disease and the role of point-of-care calprotectin. Therap.Adv. Gastroenterol. 2018 Vol 11: 1-18 5. A. Moniuszko et al. Rapid fecal calprotectin test for prediction of mucosal inflammation in UC and CD: A prospective cohort study. Pol. Arch. Internal Med. 2017. 6. T. Lobaton et al. A new rapid test for faecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn’s disease. J of Crohn’s and Colitis 2013. 7. E. Abej et al. Utility of faecal calprotectin in the real-world clinical care of patients with inflammatory bowel disease. Can. J. Gastroenterol Hepatol.2016. 8. L. Coorevits et al. Faecal calprotectin: comparative study of the Quantum Blue rapid test and an established ELISA method. Clin Chem Lab Med 2012. Find out more at: www.calprotectin.co.uk/poc See how point of care testing can impact patient care in your hospital. Contact us to request an evaluation: Email digestivedx@alphalabs.co.uk “This rapid bedside test can facilitate clinical decisions on hospital admission, such as deciding whether the IBD treatment should be intensified. Similarly, in the ambulatory setting, it is crucial when determining whether a patient should undergo endoscopy or not5” Moniuszko et al. “Introduction of routine pointof-care faecal calprotectin testing could, potentially, improve the appropriateness of clinical decisionmaking, streamline resource allocation, reduce adverse events associated with injudicious use of medications and reduce costs4” Derwa et al. “We observed that FC, measured both with fCAL ELISA and the rapid Quantum Blue, was able to discriminate between the different levels of endoscopic activity, as well as to detect the presence or absence of ulcer6” Lobaton et al. “We found that in a referral population of persons with IBD, positive fCAL was significantly associated with abnormal endoscopy, elevated serum CRP, low serum Hg, and low serum albumi7” Abej et al. Product Description Product Code Kit Size Faecal calprotectin standard range 30 - 300µg/g LF-CAL25 25 Faecal calprotectin high range 100 - 1800µg/g LF-CHR25 25 Faecal calprotectin extended range 30 – 1000µg/g LF-CALE25 25 Serum calprotectin 0.42 - 10µg/ml LF-MRP25 25 Ascites calprotectin 0.19 – 1.9µg/ml LF-ASC25 25 CRP 1-25mg/l LF-CRP25 25 Infliximab serum trough levels 0.4 - 20µg/ml (linear up to 180µg/ml) LF-TLIF25 25 LF-TLIF10 10 Adalimumab serum trough levels 1-35µg/ml LF-TLAD25 25 LF-TLAD10 10 The Quantum Blue reader can be used with a range of assays to give quantitative results in a time frame that can impact the clinical decision: Calprotectin, µg/g faeces Date Figure 3. Faecal calprotectin: comparative study of the Quantum Blue rapid test and an established ELISA method. Figure 2. FC-QPOCT (Quantum Blue fCAL) was also able to discriminate between the different grades of endoscopic activity.
RkJQdWJsaXNoZXIy MTUyODc1Mw==